Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ (CTTNKTL-Ⅲ/Ⅳ)
A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)
Sponsor: Cancer Hospital of Guizhou Province
This PHASE4 trial investigates Nasal and Nasal-type NK/T-cell Lymphoma and is currently ongoing. Cancer Hospital of Guizhou Province leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Aug 2025 — Sep 2025 [monthly]
Unknown PHASE4
-
Sep 2024 — Aug 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
▶ Show 4 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Hospital of Guizhou Province
- Mingzhi Zhang
- Qingdao University
- Second Hospital of Shanxi Medical University
- Shanxi Province Cancer Hospital
- The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Wuhan TongJi Hospital
- Wuhan University
- Xinyang Central Hospital
For direct contact, visit the study record on ClinicalTrials.gov .